Parallel Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$131K Buy
2,028
+147
+8% +$10.4K ﹤0.01% 1428
2025
Q4
$127K Sell
1,881
-6
-0.3% -$404 ﹤0.01% 1342
2025
Q3
$138K Sell
1,887
-47
-2% -$3.12K ﹤0.01% 1239
2025
Q2
$101K Buy
1,934
+59
+3% +$3.36K ﹤0.01% 1349
2025
Q1
$120K Buy
1,875
+208
+12% +$12.1K ﹤0.01% 1202
2024
Q4
$79.7K Sell
1,667
-15
-0.9% -$769 ﹤0.01% 1383
2024
Q3
$96.3K Sell
1,682
-73
-4% -$4.18K ﹤0.01% 1278
2024
Q2
$91.9K Buy
1,755
+110
+7% +$4.82K ﹤0.01% 1223
2024
Q1
$66.9K Buy
1,645
+1,279
+349% +$47.9K ﹤0.01% 1358
2023
Q4
$13.5K Sell
366
-74
-17% -$2.79K ﹤0.01% 2151
2023
Q3
$16.8K Buy
440
+168
+62% +$6.88K ﹤0.01% 1941
2023
Q2
$9.81K Buy
272
+140
+106% +$4.78K ﹤0.01% 2176
2023
Q1
$5.04K Sell
132
-23
-15% -$1.08K ﹤0.01% 2405
2022
Q4
$8.82K Sell
155
-123
-44% -$6.3K ﹤0.01% 2078
2022
Q3
$11K Buy
278
+83
+43% +$3.67K ﹤0.01% 1955
2022
Q2
$9K Buy
195
+39
+25% +$1.69K ﹤0.01% 2032
2022
Q1
$6K Buy
156
+17
+12% +$606 ﹤0.01% 2233
2021
Q4
$6K Sell
139
-208
-60% -$7.76K ﹤0.01% 2322
2021
Q3
$14K Buy
347
+254
+273% +$10.6K ﹤0.01% 1909
2021
Q2
$4K Sell
93
-59
-39% -$2.61K ﹤0.01% 2367
2021
Q1
$6K Buy
152
+59
+63% +$2.69K ﹤0.01% 2125
2020
Q4
$4K Sell
93
-175
-65% -$6.29K ﹤0.01% 2092
2020
Q3
$7K Hold
268
﹤0.01% 1892
2020
Q2
$7K Buy
268
+84
+46% +$1.9K ﹤0.01% 1841
2020
Q1
$3K Buy
184
+9
+5% +$171 ﹤0.01% 2027
2019
Q4
$3K Hold
175
﹤0.01% 2107
2019
Q3
$3K Hold
175
﹤0.01% 2058
2019
Q2
$3K Buy
+175
New +$2.82K ﹤0.01% 1985

Other funds holding HALO

Parallel Advisors's HALO Position: Q1 2026 in Review

Parallel Advisors increased its Halozyme (HALO) stake by 7.8% in Q1 2026, buying an estimated $10.4K and bringing the position to 2,028 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #1428.

Parallel Advisors first reported a position in HALO in Q2 2019 and has held it in 28 quarters since. The position peaked at $138K in Q3 2025. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Parallel Advisors held 2,028 shares of Halozyme worth $131K as of Q1 2026.
  • Parallel Advisors bought 147 Halozyme shares in Q1 2026, an estimated $10.4K.
  • Halozyme made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #1428 holding.
  • Parallel Advisors first reported a position in Halozyme in Q2 2019 and has held it in 28 quarters since.
  • Parallel Advisors's Halozyme position peaked at $138K in Q3 2025.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.